Mexico vs Tajikistan: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Mexico
78.0%
in 2025
Tajikistan
79.0%
in 2025
Mexico rank
123rd
Tajikistan rank
121st
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Mexico
- Tajikistan
How they compare
Tajikistan currently reports 79.0% against 78.0% in Mexico, a difference of 1.0%.
The two have swapped places 1 time across 18 shared years of data; in 2008 it was Mexico ahead.
Mexico ranks 123rd and Tajikistan ranks 121st of 194 countries.
Mexico has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Mexico | Tajikistan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 30.0% | 0.0% | 30.0% | Mexico |
| 2010s | 91.8% | 0.0% | 91.8% | Mexico |
| 2020s | 79.3% | 31.3% | 48.0% | Mexico |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Mexico or Tajikistan?
- Tajikistan, at 79.0% against 78.0% in Mexico as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Mexico and Tajikistan?
- 1.0%, with Tajikistan ahead.
- How many years of comparable data are there for Mexico and Tajikistan?
- 18 years are reported by both, from 2008 to 2025.
- How do Mexico and Tajikistan rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Mexico ranks 123rd and Tajikistan ranks 121st of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.